Imagio Optics-and-Sound Imaging System Distinguishes Benign from Malignant Breast Tumors

Imagio Optics-and-Sound Imaging System Distinguishes Benign from Malignant Breast Tumors
The Imagio opto-acoustic imaging (OA/US) system does a good job of distinguishing benign from malignant breast tumors, according to a Phase 3 clinical trial. Seno Medical Instruments said its system, which combines laser optics and ultrasound, works by differentiating between the masses of benign and malignant tumors. The company presented the results of the Phase 3 PIONEER clinical trial on Imagio's effectiveness at the American Roentgen Ray Society annual meeting in New Orleans, May 1-5. "These data reinforce previous findings suggesting that opto-acoustic diagnostic imaging may improve our ability to differentiate between benign and malignant breast masses,” Dr. Reni Butler, principal investigator in the trial, said in a news release. “This could help us decrease the number of unnecessary breast biopsies performed for benign findings, reducing patient anxiety, discomfort and health care cost." Seno's scientists designed Imagio to identify two cancer hallmarks: the presence of abnormal blood vessels in t
Subscribe or to access all post and page content.